Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Acute Coronary Syndrome
Interventions
DRUG

99mTc-glucarate solution

Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center

Trial Locations (4)

15213

University of Pittsburgh Medical Center, Pittsburgh

35294

University of Alabama at Birmingham, Birmingham

44106

University Hospital Case Medical Center, Cleveland

06520

Yale University, New Haven

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Yale University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

University Hospitals Cleveland Medical Center

OTHER

lead

Molecular Targeting Technologies, Inc.

INDUSTRY

NCT00614354 - Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients. | Biotech Hunter | Biotech Hunter